- Home
- TECX vs CHW Comparison
TECX vs CHW Comparison
Compare TECX & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- CHW
- Stock Information
- Founded
- TECX 2019
- CHW 2007
- Country
- TECX United States
- CHW United States
- Employees
- TECX N/A
- CHW N/A
- Industry
- TECX
- CHW Investment Managers
- Sector
- TECX
- CHW Finance
- Exchange
- TECX Nasdaq
- CHW Nasdaq
- Market Cap
- TECX 387.1M
- CHW 459.2M
- IPO Year
- TECX 2018
- CHW N/A
- Fundamental
- Price
- TECX $16.01
- CHW $7.48
- Analyst Decision
- TECX Buy
- CHW
- Analyst Count
- TECX 6
- CHW 0
- Target Price
- TECX $79.17
- CHW N/A
- AVG Volume (30 Days)
- TECX 475.2K
- CHW 195.2K
- Earning Date
- TECX 11-06-2025
- CHW 01-01-0001
- Dividend Yield
- TECX N/A
- CHW 9.27%
- EPS Growth
- TECX N/A
- CHW N/A
- EPS
- TECX N/A
- CHW N/A
- Revenue
- TECX N/A
- CHW N/A
- Revenue This Year
- TECX N/A
- CHW N/A
- Revenue Next Year
- TECX N/A
- CHW N/A
- P/E Ratio
- TECX N/A
- CHW N/A
- Revenue Growth
- TECX N/A
- CHW N/A
- 52 Week Low
- TECX $13.70
- CHW $5.07
- 52 Week High
- TECX $61.07
- CHW $6.54
- Technical
- Relative Strength Index (RSI)
- TECX 34.36
- CHW 69.59
- Support Level
- TECX $15.92
- CHW $7.20
- Resistance Level
- TECX $18.61
- CHW $7.51
- Average True Range (ATR)
- TECX 1.58
- CHW 0.08
- MACD
- TECX -0.46
- CHW 0.02
- Stochastic Oscillator
- TECX 5.59
- CHW 90.91
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.